The estimated Net Worth of Capital (Gp), Llcbaker Juli... is at least $5.99 Million dollars as of 17 December 2007. Capital Juli owns over 7,549 units of Incyte stock worth over $5,994,888 and over the last 18 years Capital sold INCY stock worth over $0.
Capital has made over 9 trades of the Incyte stock since 2007, according to the Form 4 filled with the SEC. Most recently Capital bought 7,549 units of INCY stock worth $80,019 on 17 December 2007.
The largest trade Capital's ever made was buying 21,926 units of Incyte stock on 9 November 2007 worth over $177,381. On average, Capital trades about 6,783 units every 10 days since 2006. As of 17 December 2007 Capital still owns at least 94,961 units of Incyte stock.
You can see the complete history of Capital Juli stock trades at the bottom of the page.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B..., and Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: